Skip to content

Study · Randomized controlled trial · n = 278 · 2025

4 results

Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.

Ard J, Lee CJ, Gudzune K, Addison B, Lingvay I, Cao D, Mast CJ, Stefanski A, Falcon B, Mojdami D

Diabetes, obesity & metabolism17 Jul 2025Cited by 13 (Europe PMC)

PMID40677091 (opens in a new tab)PMCIDPMC12326891 (opens in a new tab)DOI10.1111/dom.16554 (opens in a new tab)PepBankPUB-40677091
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity in SURMOUNT-1 who had under 5% weight reduction at Week 12, 194 (70%) reached at least 5% weight reduction by Week 24 on tirzepatide.

    In plain wordsIn adults with obesity who lost little weight early, most still lost at least 5% by week 24 on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseLate responders reaching at least 5% weight reduction at Week 24
    Study

    n = 278

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Late responders with at least 5% weight reduction
    194 participants
    Week 24
    Proportion
    70%
    Week 24

    Source sentences

    Summary
    At the end of dose titration, Week 24, 194 (70%) late responders achieved ≥5% body weight reduction.
    2 context sentences
    Summary · context
    This post hoc analysis included participants treated with tirzepatide who received ≥75% of the assigned treatment doses and had weight measurements at Weeks 0, 12, 24 and 72.
    Summary · context
    Participants were categorized based on the 12-week response to tirzepatide: late responders (<5% weight reduction at Week 12) or early responders (≥5% weight reduction at Week 12).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity in SURMOUNT-1 who had under 5% weight reduction at Week 12, 250 (90%) reached at least 5% weight reduction by Week 72 on tirzepatide.

    In plain wordsIn adults with obesity who lost little weight early, nine in ten still lost at least 5% by week 72 on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseLate responders reaching at least 5% weight reduction at Week 72
    Study

    n = 278

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Late responders with at least 5% weight reduction
    250 participants
    Week 72
    Proportion
    90%
    Week 72

    Source sentences

    Summary
    At Week 72, 250 (90%) late responders achieved ≥5% body weight reduction.
    2 context sentences
    Summary · context
    This post hoc analysis included participants treated with tirzepatide who received ≥75% of the assigned treatment doses and had weight measurements at Weeks 0, 12, 24 and 72.
    Summary · context
    Participants were categorized based on the 12-week response to tirzepatide: late responders (<5% weight reduction at Week 12) or early responders (≥5% weight reduction at Week 12).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In late responders to tirzepatide in SURMOUNT-1, the mean time to reach 5% weight reduction was 24.8 weeks (SD 12.7).

    In plain wordsIn adults with obesity who lost little weight early, reaching a 5% loss on tirzepatide took 24.8 weeks on average.

    Peptide
    Tirzepatide
    Outcome
    Not applicableTime to 5% weight reduction in late responders
    Study

    n = 278

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean time to 5% weight reduction
    24.8 weeks
    late responders

    Source sentences

    Summary
    The mean time to reach 5% weight reduction for late responders was 24.8 ± 12.7 weeks.
    2 context sentences
    Summary · context
    This post hoc analysis included participants treated with tirzepatide who received ≥75% of the assigned treatment doses and had weight measurements at Weeks 0, 12, 24 and 72.
    Summary · context
    Participants were categorized based on the 12-week response to tirzepatide: late responders (<5% weight reduction at Week 12) or early responders (≥5% weight reduction at Week 12).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In tirzepatide-treated adults with obesity, higher doses were associated with higher proportions reaching various weight reduction thresholds at Weeks 24 and 72.

    In plain wordsIn adults with obesity on tirzepatide, higher doses were linked to more people reaching each weight loss goal.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight reduction thresholds by tirzepatide dose at Weeks 24 and 72
    Study

    n: not reported in source

    Comparator
    Lower tirzepatide doses
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Higher doses of tirzepatide were associated with higher proportions of participants achieving various weight reduction thresholds at Weeks 24 and 72.
    2 context sentences
    Summary · context
    This post hoc analysis included participants treated with tirzepatide who received ≥75% of the assigned treatment doses and had weight measurements at Weeks 0, 12, 24 and 72.
    Summary · context
    Participants were categorized based on the 12-week response to tirzepatide: late responders (<5% weight reduction at Week 12) or early responders (≥5% weight reduction at Week 12).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04184622

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Eli Lilly and Companyn = 2,5394 Dec 2019 to 6 Jul 2024

Overweight · Obesity

Trial pageClinicalTrials.govUpdated 24 Jul 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.